Condition 1: Chronic Joint Diseases. Condition 2: Chronic Joint Diseases. Condition 3: Chronic Joint Diseases. Condition 4: Chronic Joint Diseases. Condition 5: Chronic Joint Diseases. Condition 6: Chronic Joint Diseases. Rheumatoid arthritis with rheumatoid factor Other rheumatoid arthritis Polyosteoarthritis Other and unspecified osteoarthritis Ankylosing spondylitis Other arthritis
Conditions
Interventions
Intervention 1: In the intervention arm, patients will receive low-dose radiotherapy (LDRT). Before treatment, a CT-simulation scan is performed to define the target volume, determine the isocenter, a
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: Age = 50 years A confirmed diagnosis of one of the chronic joint disorders—RA, OA, AS, PsA, epicondylitis, or plantar fasciitis—established by a rheumatologist, orthopedic specialist, or radiation oncologist (supported by imaging findings) Persistent pain and significant functional impairment in the target joint, with a history of treatment-refractory symptoms for = 3 months. Confirmation of metabolic or inflammatory activity in the target joint using bone scan or SPECT/SPECT-CT (or PET), if needed and available Written informed consent from the patient. Acceptable general performance status for radiotherapy (ECOG = 2)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain intensity. Timepoint: at baseline, week 4 (for early-response assessment), and week 12. Method of measurement: A 0–10 visual analogue scale is used to assess pain intensity, completed by the patient. Higher scores indicate more severe paiN.;The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for OA. Timepoint: at baseline, week 4 (for early-response assessment), and week 12. Method of measurement: This questionnaire is specifically designed for OA patients and effectively reflects clinical changes following treatment.The WOMAC includes 24 items across three subscales: pain (5 items), stiffness (2 items), and physical function (17 items).Each item is scored using a rating scale (typically a 0–4 Likert scale or a 0–10 visual analogue scale), with higher scores indicating greater symptom severity.;Quality of life (EQ-5D-5L). Timepoint: at baseline, week 4 (for early-response assessment), and week 12. Method of measurement: A standard tool assessing health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.Its scores are used to generate an overall quality-of-life index and evaluate the patient’s self-reported health status.;ECOG Performance Status. Timepoint: at baseline, week 4 (for early-response assessment), and week 12. Method of measurement: A 0–5 scale is used to assess the patient’s daily functional capacity, where 0 indicates full function and 5 indicates death.???????? ???????.;Inflammatory markers. Timepoint: at baseline, week 4 (for early-response assessment), and week 12. Method of measurement: Including CRP, ESR, NLR, and PLR.These markers are primarily used to assess inflammatory activity in inflammatory joint diseases (such as RA and ankylosing spondylitis), and their changes will be monitored in response to treatment.In patients with osteoarthritis (OA), which is predominantly non-inflammatory, these markers may remain within normal ranges, and the ma | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNaghmeh Ramezani
Tabriz University of Medical Sciences
Outcome results
None listed